Menu

AbbVie has announced 340B contract pharmacy restrictions for a new federally approved drug used to treat a rare and aggressive form of blood cancer.

AbbVie Adds 340B CP Restrictions to New Blood Cancer Drug

July 7, 2026 Shannon Young, Managing Editor 340B Report Views

AbbVie recently announced 340B contract pharmacy restrictions for its new federally approved drug used to treat Blastic plasmacytoid dendritic cell [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

U.S. House Lawmakers Unveil Bipartisan 340B Reform Bill

Major Hospital Trade Group Names Next President and CEO